ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 027

Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition

Sofia Torreggiani1, Pascal Pillet 2, Fabiano de Oliveira Poswar 3, Anna Kozlova 4, Anna Shcherbina 4, Marietta De Guzman 5, Jacob Mitchell 6, Gina A. Montealegre Sanchez 7, Katherine Townsend 8, Kim Johnson 9, Adriana Almeida de Jesus 10 and Raphaela Goldbach-Mansky 11, 1National Institutes of Health, Bethesda, 2Bordeaux Cedex, France, 3Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, 4Center for Pediatric Hematology, Oncology, Immunology, Moscow, Russia, 5Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 6NIAID, NIH, Bethesda, 7NIH/ NIAID, Rockville, 8NIH, 9NIH, NIAID, Bethesda, 10NIAID, NIH, Silver Spring, 11NIH/NIAID, Potomac

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Autoinflammatory Disease, interferons, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Breakout 4 – Updates on Therapeutics

Session Type: Poster Breakout Session

Session Time: 4:30PM-5:00PM

Background/Purpose: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy And Elevated Temperature (CANDLE) Syndrome is an autoinflammatory interferonopathy caused by mutations in the genes encoding for components or chaperone proteins required for proteasome assembly. CANDLE Syndrome is characterized by inflammatory and metabolic manifestations. Long-term outcomes, especially after introduction of treatment with JAK-inhibitors, are little known. Our aim is to describe the clinical disease manifestations and laboratory findings in patients with CANDLE, before and after treatment with a JAK-inhibitor.

Methods: Medical records of 22 patients with genetically confirmed CANDLE Syndrome were retrospectively reviewed. The IFN score was calculated as previously described [1].

Results: Twenty-two patients were included in the study, 12 (55%) were females. The p.T75M homozygous mutation in PSMB8 was the most common genotype (50%). Disease always presented in the first year of life, mostly within the first month (68%) and with rash (90.9%). Median age at last evaluation was 12 years (range 1-30). Table 1 summarizes the clinical and laboratory features that occurred over time. Table 2 displays clinical and laboratory features at disease presentation and at last visit. Steroids were administered in 19/21 patients. Fifteen patients were treated with a JAK-inhibitor (10 with baricitinib, 4 with tofacitinib, 1 with ruxolitinib), for a median period of 4.29 years (range 0.75-7.09). In the majority of treated patients, rash, fever, musculoskeletal pain and fatigue resolved. Metabolic syndrome and hepatic steatosis occurred both before and after starting JAK-inhibitor treatment and improved in 2 patients who adopted lifestyle changes and received specific treatment (fenofibrate and/or metformin). Four patients deceased, of whom two had been treated with a JAK inhibitor, for 9 months and 1.5 years respectively. One had already developed significant pulmonary hypertension when treatment was started; the other had stopped baricitinib due to renal insufficiency. Outcomes are summarized in Table 3.

Conclusion: While fever, rash and increased inflammatory markers are universal features CANDLE Syndrome, other findings vary significantly among patients, without a clear genotype-phenotype correlation. Hepatic steatosis and pulmonary hypertension were unrecognized at presentation. Treatment with JAK inhibitors can decrease inflammatory manifestations. Metabolic abnormalities did not appear to be improved by JAK-inhibitor treatment, while lifestyle changes, and treatments with lipid-lowering agents and targeting insulin resistance, resolved metabolic syndrome and hepatic steatosis in 2 patients.

 

Funding for this study was provided by the Division of Intramural Research, NIAID, NIH

  1. Kim H, de Jesus AA, Brooks SR, Liu Y, Huang Y, VanTries R., et al.Development of a validated interferon score using nanostring technology. J Interferon Cytokine Res 2018; 38: 171–85.

Table 1. Clinical and laboratory features of CANDLE patients included in the study. For each item, the denominator indicates the number of patients with available data.

Table 2. Clinical and laboratory features at disease presentation and at last visit. For each item, the denominator indicates the number of patients with available data.

Table 3. Outcomes in patients treated and not treated with JAK_inhibitors. For each item, the denominator indicates the number of patients with available data.


Disclosure: S. Torreggiani, None; P. Pillet, None; F. de Oliveira Poswar, None; A. Kozlova, None; A. Shcherbina, None; M. De Guzman, None; J. Mitchell, None; G. Montealegre Sanchez, None; K. Townsend, None; K. Johnson, None; A. Almeida de Jesus, None; R. Goldbach-Mansky, Lilly, 1.

To cite this abstract in AMA style:

Torreggiani S, Pillet P, de Oliveira Poswar F, Kozlova A, Shcherbina A, De Guzman M, Mitchell J, Montealegre Sanchez G, Townsend K, Johnson K, Almeida de Jesus A, Goldbach-Mansky R. Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/clinical-features-and-outcomes-in-chronic-atypical-neutrophilic-dermatosis-with-lipodystrophy-and-elevated-temperature-candle-syndrome-before-and-after-jak-inhibition/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-and-outcomes-in-chronic-atypical-neutrophilic-dermatosis-with-lipodystrophy-and-elevated-temperature-candle-syndrome-before-and-after-jak-inhibition/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology